Richard Geary Sells 1,680 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Richard Geary sold 1,680 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $75.05, for a total value of $126,084.00. Following the transaction, the executive vice president directly owned 59,657 shares in the company, valued at approximately $4,477,257.85. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ionis Pharmaceuticals Trading Down 1.0%

IONS opened at $72.88 on Wednesday. The firm has a market cap of $11.80 billion, a price-to-earnings ratio of -43.12 and a beta of 0.33. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $75.49. The business’s 50 day moving average is $65.22 and its two-hundred day moving average is $47.42. The company has a quick ratio of 2.86, a current ratio of 2.87 and a debt-to-equity ratio of 0.99.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.35. The company had revenue of $157.00 million for the quarter, compared to analyst estimates of $131.75 million. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 26.45%.The firm’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.95) earnings per share. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current year.

Institutional Trading of Ionis Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Golden State Wealth Management LLC boosted its stake in shares of Ionis Pharmaceuticals by 198.4% in the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after buying an additional 250 shares in the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $25,000. Mather Group LLC. purchased a new stake in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $27,000. Meeder Asset Management Inc. boosted its stake in shares of Ionis Pharmaceuticals by 620.2% in the third quarter. Meeder Asset Management Inc. now owns 713 shares of the company’s stock valued at $47,000 after buying an additional 614 shares in the last quarter. Finally, Allworth Financial LP boosted its stake in shares of Ionis Pharmaceuticals by 231.8% in the second quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after buying an additional 517 shares in the last quarter. 93.86% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on IONS shares. Royal Bank Of Canada lifted their price target on Ionis Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Cowen set a $99.00 target price on Ionis Pharmaceuticals in a report on Thursday, October 30th. Oppenheimer boosted their target price on Ionis Pharmaceuticals from $84.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, October 8th. Wells Fargo & Company boosted their target price on Ionis Pharmaceuticals from $77.00 to $82.00 and gave the company an “overweight” rating in a report on Friday, August 22nd. Finally, Bank of America boosted their target price on Ionis Pharmaceuticals from $81.00 to $83.00 and gave the company a “buy” rating in a report on Tuesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $83.65.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.